Wednesday, May 3rd, 2017, 7:55 am - 8:45 am

Location: Boston Scientific Ballroom

CV/metabolic disorders comprise aggregates of many niche diseases that may be targeted with therapies against specific molecular alterations, yet the final potential markets are much larger. This model creates challenges for both drug development and patient care with implications for initial indication selection and design and execution of clinical trials – from first-in-human through post marketing studies.

 

Innovation in Translational Trials

Wednesday, May 3rd, 2017, 7:55 am - 8:45 am

Location: Boston Scientific Ballroom

CV/metabolic disorders comprise aggregates of many niche diseases that may be targeted with therapies against specific molecular alterations, yet the final potential markets are much larger. This model creates challenges for both drug development and patient care with implications for initial indication selection and design and execution of clinical trials – from first-in-human through post marketing studies.